CYP27B1 and chronic kidney disease: When renal CYP27B1 declines in advancing CKD, its extrarenal counterparts can be engaged therapeutically to become major alternative sources of 1,25D, thereby restoring normal vitamin D metabolism, as illustrated by trials with extended-release calcifediol (ERC) in adults with stage 3, 4 or 5 CKD.4,5